$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415028495 Filed on May 07, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$14.00M	$9.877M	$7.462M
YoY Change	69.46%	32.36%	94.68%
Cost Of Revenue	$2.700M	$2.500M	$3.021M
YoY Change	-47.08%	-17.25%	76.46%
Gross Profit	$11.30M	$7.377M	$4.441M
YoY Change	257.81%	66.11%	109.38%
Gross Profit Margin	80.71%	74.69%	59.51%
Selling, General & Admin	$7.100M	$5.800M	$4.300M
YoY Change	22.41%	34.88%	48.28%
% of Gross Profit	62.85%	78.62%	96.83%
Research & Development	$27.73M	$28.35M	$14.52M
YoY Change	82.4%	95.25%	56.85%
% of Gross Profit	245.48%	384.26%	326.91%
Depreciation & Amortization	$1.500M	$1.300M	$1.000M
YoY Change	50.0%	30.0%	150.0%
% of Gross Profit	13.28%	17.62%	22.52%
Operating Expenses	$27.73M	$28.35M	$14.52M
YoY Change	82.4%	95.25%	56.85%
Operating Profit	-$20.82M	-$24.31M	-$14.39M
YoY Change	16.64%	69.02%	43.78%
Interest Expense	$26.00K	$36.00K	$52.00K
YoY Change	-49.02%	-30.77%	136.36%
% of Operating Profit
Other Income/Expense, Net	$72.00K	-$142.0K	$0.00
YoY Change	300.0%
Pretax Income	-$20.60M	-$24.40M	-$13.81M
YoY Change	15.32%	76.68%	38.39%
Income Tax
% Of Pretax Income
Net Earnings	-$20.64M	-$24.37M	-$13.81M
YoY Change	15.55%	76.47%	38.16%
Net Earnings / Revenue	-147.48%	-246.73%	-185.07%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.537M	-$2.017M	-$1.327M
COMMON SHARES
Basic Shares Outstanding	268.0M shares	239.4M shares	209.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$314.9M	$327.7M	$112.8M
YoY Change	106.49%	190.51%	154.63%
Cash & Equivalents	$167.4M	$215.1M	$109.9M
Short-Term Investments	$147.6M	$112.7M	$2.900M
Other Short-Term Assets	$13.20M	$11.50M	$504.0K
YoY Change	4807.06%	2181.75%	-43.12%
Inventory
Prepaid Expenses			$4.626M
Receivables	$2.342M	$6.674M	$4.466M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$333.0M	$350.1M	$128.9M
YoY Change	99.86%	171.66%	149.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.13M	$23.97M	$14.27M
YoY Change	72.8%	67.95%	22.84%
Goodwill	$53.31M	$52.66M	$58.62M
YoY Change	-7.94%	-10.16%	76.88%
Intangibles	$11.36M	$11.20M	$15.92M
YoY Change	-24.72%	-29.65%
Long-Term Investments
YoY Change
Other Assets	$918.0K	$918.0K	$159.0K
YoY Change	477.36%	477.36%	-54.57%
Total Long-Term Assets	$91.72M	$88.75M	$89.73M
YoY Change	-36.91%	-1.09%	90.98%
TOTAL ASSETS
Total Short-Term Assets	$333.0M	$350.1M	$128.9M
Total Long-Term Assets	$91.72M	$88.75M	$89.73M
Total Assets	$424.7M	$438.8M	$218.6M
YoY Change	36.13%	100.75%	121.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.117M	$9.742M	$4.018M
YoY Change	58.33%	142.46%	84.91%
Accrued Expenses	$16.52M	$15.59M	$8.208M
YoY Change	50.23%	89.94%	40.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$600.0K	$1.000M
YoY Change	-44.44%	-40.0%	150.0%
Total Short-Term Liabilities	$27.05M	$28.78M	$13.72M
YoY Change	54.77%	109.81%	48.22%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$300.0K	$1.100M
YoY Change	-88.89%	-72.73%	-26.67%
Other Long-Term Liabilities	$73.00K	$91.00K	$1.562M
YoY Change	-95.16%	-94.17%	-84.98%
Total Long-Term Liabilities	$73.00K	$91.00K	$1.562M
YoY Change	-95.16%	-94.17%	-86.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.05M	$28.78M	$13.72M
Total Long-Term Liabilities	$73.00K	$91.00K	$1.562M
Total Liabilities	$37.10M	$39.14M	$27.54M
YoY Change	22.59%	42.11%	30.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$538.1M	-$517.5M	-$424.0M
YoY Change	21.79%	22.06%	15.16%
Common Stock	$2.691M	$2.684M	$2.097M
YoY Change	12.78%	27.99%	38.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares		455.4K shares	455.4K shares
Shareholders Equity	$387.6M	$399.7M	$191.1M
YoY Change
Total Liabilities & Shareholders Equity	$424.7M	$438.8M	$218.6M
YoY Change	36.13%	100.75%	121.47%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$20.64M	-$24.37M	-$13.81M
YoY Change	15.55%	76.47%	38.16%
Depreciation, Depletion And Amortization	$1.500M	$1.300M	$1.000M
YoY Change	50.0%	30.0%	150.0%
Cash From Operating Activities	-$12.30M	-$30.50M	-$20.43M
YoY Change	11.82%	49.28%	93.05%
INVESTING ACTIVITIES
Capital Expenditures	-$4.300M	-$4.900M	-$900.0K
YoY Change	377.78%	444.44%	-40.0%
Acquisitions
YoY Change
Other Investing Activities	-$35.10M	$22.70M	$10.60M
YoY Change	-65.52%	114.15%	-411.76%
Cash From Investing Activities	-$39.40M	$17.80M	$9.701M
YoY Change	-61.67%	83.49%	-295.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$193.6M	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.100M	195.5M	$1.170M
YoY Change	-96.19%	16609.4%	-83.71%
NET CHANGE
Cash From Operating Activities	-12.30M	-30.50M	-$20.43M
Cash From Investing Activities	-39.40M	17.80M	$9.701M
Cash From Financing Activities	4.100M	195.5M	$1.170M
Net Change In Cash	-47.60M	182.8M	-$9.560M
YoY Change	680.33%	-2012.13%	14.14%
FREE CASH FLOW
Cash From Operating Activities	-$12.30M	-$30.50M	-$20.43M
Capital Expenditures	-$4.300M	-$4.900M	-$900.0K
Free Cash Flow	-$8.000M	-$25.60M	-$19.53M
YoY Change	-20.79%	31.07%	115.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2	pure
CY2012	nvax	Clinical Trial Costs Incurred ClinicalTrialCostsIncurred	2900000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15359430	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23250163	shares
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1394000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13884000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1307000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11198000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12577000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-13810000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-24370000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	980000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1309000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-99000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215050000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32335000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12592000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2057000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1170000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1932000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	195496000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193619000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1345000	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-427000	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	213000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1040000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1081000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-297000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2559000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1018000	USD
CY2014Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1125000	USD
CY2015Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1096000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1516000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2491000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4007000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7574000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-215000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	107000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20431000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30490000	USD
CY2014Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	889000	USD
CY2015Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4864000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10590000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	29450000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9701000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	17788000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	16000	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-168000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-164000	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	10000	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-79000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9550000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	182715000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119471000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109921000	USD
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	214000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3118000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	52000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	31000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	297000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6674000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7510000	USD
CY2015Q1	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4196000	USD
CY2014Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	3100000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	350094000	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	188158000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23967000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19737000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11198000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12577000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	52664000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	54612000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	918000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	918000	USD
CY2015Q1	us-gaap	Assets Assets	438841000	USD
CY2014Q4	us-gaap	Assets Assets	276002000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9742000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12908000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15590000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19397000	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	579000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	603000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1161000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1138000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	28776000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34116000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2015Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	252000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	395000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7516000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7734000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	91000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1639000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	39135000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	46384000	USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	2684000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2393000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	926691000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	729373000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517463000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-493093000	USD
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9756000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6605000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	399706000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	229618000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	438841000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276002000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	615000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-749000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-133000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3194000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3151000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14559000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14385000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27521000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	5472000	USD
CY2015Q1	us-gaap	Contracts Revenue ContractsRevenue	9246000	USD
CY2014Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1990000	USD
CY2015Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	631000	USD
CY2014Q1	us-gaap	Revenues Revenues	7462000	USD
CY2015Q1	us-gaap	Revenues Revenues	9877000	USD
CY2014Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	3021000	USD
CY2015Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	2459000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14518000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25888000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4308000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5843000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	21847000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	34190000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24313000	USD
CY2014Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2015Q1	us-gaap	Investment Income Net InvestmentIncomeNet	121000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	52000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	36000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142000	USD
CY2014Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	615000	USD
CY2015Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	208927	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	241223	shares
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	628000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.63
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0119	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5247	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5358	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6793	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5389	pure
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M4D
CY2015Q1	nvax	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.1633	pure
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1040000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	81400000	USD
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1400000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3800000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12500000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	45500000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.48
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.48
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	837000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	837000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	837000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	837000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	837000	USD
CY2015Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-1948000	USD
CY2015Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	112705000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	135786000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	8000	USD
CY2015Q1	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	6000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	73000	USD
CY2015Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	26000	USD
CY2015Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	112685000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	135721000	USD
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 1 Organization</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiary “Novavax AB,” the “Company”) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company’s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (“RSV”), seasonal influenza, pandemic influenza and Ebola virus (“EBOV”). The Company has additional preclinical stage programs in a variety of infectious diseases, including Middle East Respiratory Syndrome (“MERS”).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	268381979	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	239287294	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	267926549	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	238831864	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2015Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	112685000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	135721000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11489000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9195000	USD
CY2015Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1704000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	9700000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	6500000	USD
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6798000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-146000	USD
CY2015Q1	nvax	Available For Sale Securities Number Of Securities Owned AvailableForSaleSecuritiesNumberOfSecuritiesOwned	35	shares
CY2015Q1	nvax	Available For Sale Securities Number Of Securities Owned Unrealized Losses AvailableForSaleSecuritiesNumberOfSecuritiesOwnedUnrealizedLosses	29	shares
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	800000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	800000	USD
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q1	dei	Trading Symbol TradingSymbol	NVAX
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	268029873	shares
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11600000	USD

Files In Submission

Name	View Source	Status
0001144204-15-028495-index-headers.html	Edgar Link	pending
0001144204-15-028495-index.html	Edgar Link	pending
0001144204-15-028495.txt	Edgar Link	pending
0001144204-15-028495-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nvax-20150331.xml	Edgar Link	completed
nvax-20150331.xsd	Edgar Link	pending
nvax-20150331_cal.xml	Edgar Link	unprocessable
nvax-20150331_def.xml	Edgar Link	unprocessable
nvax-20150331_lab.xml	Edgar Link	unprocessable
nvax-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v408229_10q.htm	Edgar Link	pending
v408229_ex31-1.htm	Edgar Link	pending
v408229_ex31-2.htm	Edgar Link	pending
v408229_ex32-1.htm	Edgar Link	pending
v408229_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2015 Q2 Form 10-Q Financial Statement

#000114420415028495 Filed on May 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2015 Q2 Form 10-Q Financial Statement

#000114420415028495 Filed on May 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax